Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
Open Access
- 10 May 2023
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 12 (13) , 13978-13990
Abstract
Hepatocellular carcinoma (HCC) is a major cause of death among patients with liver cirrhosis. The rise of immuno‐oncology has revolutionized treatment for advanced HCC. However, most pivotal randomized controlled trials have excluded patients with moderate liver dysfunction (Child–Pugh–Turcotte B), despite the high incidence of liver disease in patients with HCC at the time of diagnosis. Overall survival in patients with HCC and moderate liver dysfunction treated with sorafenib has been found to be only approximately 3–5 months, underlining the need for improved treatment algorithms for this increasingly important subgroup of patients. In this review, we summarize available data on the treatment of patients with HCC and moderate liver dysfunction. Opportunities, as well as clinical challenges, are discussed in detail, highlighting potential changes to the therapeutic landscape.Keywords
This publication has 98 references indexed in Scilit:
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnnals of Oncology, 2012
- Obesity is an independent risk factor for clinical decompensation in patients with cirrhosisHepatology, 2011
- Surveillance for hepatocellular carcinoma: in whom and how?Therapeutic Advances in Gastroenterology, 2010
- Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?Journal of Clinical Oncology, 2010
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301Journal of Clinical Oncology, 2009
- A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapyCancer, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trialsAnnals of Oncology, 2008
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006